Every 10-Q that ArriVent BioPharma, Inc. (AVBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVBP filings page.
ArriVent BioPharma, Inc. reported continued operating losses as it advances oncology programs, led by EGFR inhibitor firmonertinib and ADC ARR-217. For the six months ended June 30, 2026, the company recorded a net loss of $93.2 million, slightly improved from $95.8 million a year earlier. Research and development expenses were $80.0 million versus $89.0 million, reflecting lower early-stage program spend after a prior-year $40.0 million upfront payment, partly offset by higher Phase 3 trial and personnel costs. General and administrative expenses increased to $18.8 million from $11.4 million due to headcount and professional services.
Cash, cash equivalents and short-term investments totaled $373.1 million as of June 30, 2026, which the company states is sufficient to fund planned operations for at least twelve months from the financial statement issuance date. Liquidity was strengthened by $140.0 million in net proceeds from sales of 5,358,318 common shares under an at-the-market program, and an undrawn $75.0 million term loan facility. ArriVent also disclosed significant contingent milestone and royalty obligations under multiple licensing and collaboration agreements and outlined a new collaboration and license arrangement granting Allist rights to ARR-002 in Greater China.
ArriVent BioPharma reported first-quarter 2026 results showing continued investment in its oncology pipeline and a narrower loss. Net loss was $43.3 million, compared with $64.4 million a year earlier, driven mainly by lower early-stage R&D spending.
Research and development expense fell to $37.6 million from $61.3 million, while general and administrative costs rose to $8.5 million as the company scales public-company operations. ArriVent ended March 31, 2026 with $326.4 million in cash, cash equivalents and marketable securities and believes this will fund operations for at least 12 months.
Pipeline progress included ongoing Phase 3 trials of firmonertinib in EGFR-mutant NSCLC and a Phase 1 trial of antibody-drug conjugate ARR-217. The company also raised $54.7 million net by selling 2.4 million shares via its at-the-market equity program and retains access to an undrawn $75 million term loan facility.
ArriVent BioPharma (AVBP) filed its Q3 2025 10-Q, reporting a net loss of $34,978 thousand for the quarter and $130,764 thousand year-to-date as it advances oncology programs led by firmonertinib. Operating expenses rose with research and development at $32,167 thousand in Q3 (driven by Phase 3 FURVENT and early-stage programs) and general and administrative at $6,149 thousand. Interest and investment income was $3,338 thousand.
Liquidity strengthened: cash and cash equivalents were $112,672 thousand and short-term investments were $187,594 thousand at September 30, 2025. The company states aggregate cash, cash equivalents and marketable securities of $305.4 million as of September 30, 2025 are sufficient to sustain planned operations through at least twelve months from the issuance date. Capital actions included $87.3 million net through an at-the-market program and $80.6 million net from a July underwritten offering. A $75.0 million term loan facility remains undrawn. Clinical updates highlight firmonertinib across multiple EGFR-mutant NSCLC settings, including a pivotal Phase 3 and a planned randomized Phase 3 study. Shares outstanding were 41,281,361 as of November 7, 2025.
ArriVent BioPharma (AVBP) is a clinical-stage biotech focused on firmonertinib and ADC programs. The company reported strong liquidity with $112.8M cash and $141.7M marketable securities (total ~$254.5M), and completed equity raises including $81.9M from an ATM program and a subsequent $81.1M underwritten offering, and has an undrawn $75M term loan commitment.
Operations show increasing investment in development: a $95.8M net loss and $94.1M net cash used in operating activities for the six months reported, driven by $89.0M of R&D spend and growing G&A. Clinical interim data for firmonertinib cited high response rates (e.g., 79% ORR in one cohort and durable responses; FURTHER interim: 16.0 months PFS and 14.6 months DOR at 240 mg), supporting continued development. The company holds substantial contingent milestone and royalty obligations under its licenses (e.g., up to $765M to Allist and ~$1.17B to Lepu).